patent.fyi
Applications  /  US 2026/0355202
United States Patent Application Publication

US 2026/0355202 A1

Published
Nov 12, 2026
Filed
Jun 26, 2026
Earliest date on the face
May 5, 2021
Classification
A61K 31/519
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1SHP2 silencing with RNA

What ifWhat if a short interfering RNA lowers SHP2 expression while an EGFR tyrosine kinase inhibitor blocks receptor activity?
Claim language“a compound of Formula (Ia)”

A lipid nanoparticle carries a short interfering RNA duplex into cells. The guide strand directs cleavage of PTPN11 messenger RNA, reducing SHP2 protein production and limiting signaling from receptor tyrosine kinases to RAS.

1.1RAS activation blocked at SOS1

What ifWhat if a small molecule blocks SOS1-mediated activation of RAS while an EGFR tyrosine kinase inhibitor blocks receptor activity?
Claim language“a compound of Formula (Ia)”

The small molecule binds SOS1 and disrupts its interaction with GDP-bound RAS. This reduces nucleotide exchange and lowers the fraction of RAS in the active, GTP-bound state.

1.1Extracellular EGFR ligand blockade

What ifWhat if an extracellular antibody blocks ligand-dependent EGFR activation while the SHP2-directed compound suppresses downstream signaling?
Claim language“an EGFR TK inhibitor”

The antibody binds the extracellular domain of EGFR and blocks ligand binding. This reduces ligand-driven receptor dimerization and autophosphorylation.

1.1EGFR transcript reduction by antisense

What ifWhat if an antisense oligonucleotide lowers EGFR abundance while the SHP2-directed compound suppresses downstream signaling?
Claim language“an EGFR TK inhibitor”

A gapmer with a central DNA segment and chemically modified terminal nucleotides hybridizes to EGFR messenger RNA. Ribonuclease H1 cleaves the RNA strand, reducing the amount of transcript available for receptor synthesis.

1.1ERK signaling blocked at MEK

What ifWhat if a MEK inhibitor suppresses ERK signaling downstream of EGFR while the SHP2-directed compound limits input to RAS?
Claim language“an EGFR TK inhibitor”

An allosteric small molecule binds MEK1 and MEK2 and reduces their phosphorylation of ERK1 and ERK2. The two agents act at separate points in the receptor-to-ERK signaling pathway.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Specific version of a part

Reversible ATP pocket inhibition

A reversible small molecule occupies the ATP-binding pocket of the intracellular EGFR kinase domain. Competition with ATP reduces phosphorylation of tyrosine residues on the receptor tail.

Covalent EGFR kinase inhibition

An ATP-pocket binding group positions an acrylamide near cysteine 797 in the EGFR kinase domain. The acrylamide reacts with the cysteine thiol to form a covalent bond that maintains inhibition after the free inhibitor dissociates from other binding sites.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2011/0207752 A1
Published
Aug 25, 2011
Filed
Nov 4, 2009
Class
A61K 31/519
Document BUS 2016/0158235 A1
Published
Jun 9, 2016
Filed
Dec 8, 2015
Class
A61K 31/517
Claim 1
Document A
Document B
1.1a compound of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof: and an EGFR TK inhibitor (epidermal growth factor receptor tyrosine kinase inhibitor).
The term “combination therapy” refers to treatment comprising the administration of the compound 4-[4-[4-(4-fluoro-3-trifluoromethyl-phenyl)-1-methyl-1H-imidazol-2-yl]-piperidin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine, or a pharmaceutically acceptable salt thereof, and an EGFR inhibitor (the “therapeutic agents”) in combination.
A · US 2011/0207752 A1 · ¶ 12
An EGFR kinase inhibitor compound (including pharmaceutically acceptable salts thereof) used in this invention, can also be included in pharmaceutical compositions in combination with one or more other therapeutically active compounds. Other therapeutically active compounds may include those cytotoxic, chemotherapeutic or anti-cancer agents, or agents which enhance the effects of such agents, as listed above.
B · US 2016/0158235 A1 · ¶ 204

An empty cell means only that no passage was reproduced there.

Statements in these documents
Furthermore, there is a need for therapies having greater efficacy than existing therapies.
A · US 2011/0207752 A1 · ¶ 3
Preferred combination therapies of the present invention show greater efficacy than treatment with either therapeutic agent alone.
A · US 2011/0207752 A1 · ¶ 3
In particular, the present invention is directed to methods for determining which patients will most benefit from treatment with an epidermal growth factor receptor (EGFR) kinase inhibitor.
B · US 2016/0158235 A1 · ¶ 2
These observations suggests that specific mutant forms of the EGF receptor may reflect a greater sensitivity to EGF receptor inhibitors, but do not identify a completely non-responsive phenotype.
B · US 2016/0158235 A1 · ¶ 6
Cite aspatent.fyi, US 2026/0355202 A1, claim 1, first published 2026-11-19T09:07:06-05:00, https://patent.fyi/US20260355202/, SHA-256 c5250521bc9431c4f030b454cf95d9c696f946cd8f909dd01979458c314b7049
First published
Permanent addresshttps://patent.fyi/US20260355202/
Content fingerprint (SHA-256)c5250521bc9431c4f030b454cf95d9c696f946cd8f909dd01979458c314b7049
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi